Compare CSX Corporation (CSX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Viatris Inc — how do they compare? CSX Corporation trades at $47.6 (market cap $87.70B), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: CSX Corporation is far larger — about 4.4× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and Viatris Inc for 57 Days on average.
| CSX | VTRS | |
|---|---|---|
Market Cap | $87.70B | $20.03B |
Volume | 6,980,781 | 14,109,977 |
Sector | Industrials | Health |
52-Week High | $53.21 | $18.27 |
52-Week Low | $33.68 | $9.74 |
Typical Hold Time | 55 Days | 57 Days |
Enterprise Value | $105.66B | $32.15B |
Dividend Yield | 1.18% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $46.81, down 1.45% with a bearish technical signal. The railroad operator shows mixed fundamentals with declining revenue from $14.9B in 2022 to $14.1B in 2025, though net income margins remain strong at 22.21%. Recent earnings show two beats and one miss, with Q3 2026 results pending. Analyst consensus is bullish with 59% buy ratings and a $51 price target, representing 9% upside from current levels.
CSX offers steady dividend income and pricing power in an irreplaceable freight network, but faces revenue pressure and elevated valuation multiples. The stock's investment case hinges on operational efficiency gains and freight volume recovery, balanced against economic sensitivity and competitive pressures in the transportation sector.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
